289 results about "Pyrazine" patented technology

The application belongs to the technical field of etching liquid, and particularly relates to an anti-crystallization copper etching liquid and a preparation method and application thereof. The copper etching liquid is obtained by mixing hydrogen peroxide, inorganic acid, organic acid, fluorine compound, hydrogen peroxide stabilizer, organic sulfonic acid sodium salt, pyrazine polycarboxylic acid, amino acid ionic liquid and water. The components in the copper etching liquid jointly act, so that the phase stability of the copper etching liquid is significantly improved, the copper etching liquid can avoid crystallization in long-time work, and is suitable for industrial application.

This disclosure provides redox cyclable molecules for energy storage. These molecules belong to either the 4H-pyran-4-ylidene family or include a six-membered aromatic ring with one nitrogen atom at position 1 (pyridinium family) or two nitrogen atoms at positions 1 and 4 (pyrazinium family) or at positions 1 and 3 (pyrimidinium family). Molecules in these families are used as analytes in redox flow batteries.

This invention relates to formula I: This relates to the compounds of JPEG2026512972000438.jpg4271, methods for their manufacture, pharmaceutical compositions containing them, and their use in the treatment of conditions related to the function of metabotropic glutamate receptor subtype 4 (mGluR4), in particular, and / or in the prevention of such conditions. A, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 The terms have the meanings provided herein.

The invention relates to the technical field of DNA intercalating agents, in particular to a near-infrared luminous ruthenium (II) complex, a preparation method thereof and application of the complex as a DNA intercalating agent. The preparation method comprises the following steps: firstly, preparing a precursor 4 '-(1H-benzimidazole-2-yl)-2, 2': 6 ', 2' '-terpyridyl; then, preparing a target precursor, namely, 2-(4-(anthracene-10-yl)-6-(pyrazine-2-yl) pyridine-2-yl) pyrazine as a ligand; and finally, synthesizing a complex [Ru (An-di (2-Pz) Py) (Bitpy)]. The complex is inserted into a DNA base pair as an intercalating agent, has very strong interaction with DNA, and provides basic research for researching the interaction mode of the ruthenium (II) polypyridine complex of the tridentate ligand and DNA and taking the ruthenium (II) polypyridine complex as a diagnosis and treatment reagent.

To provide crystalline forms of a C-C chemokine receptor type 4 antagonist.SOLUTION: There is provided the compound 2 - ((R) - 3 - (1 - (1 - ((R) - 1 - (2, 4-dichlorophenyl) ethyl) - 3 - (trifluoromethyl) - 1H - pyrazolor3, 4-b] pyrazin-6-yl) azetidin-3-yl) piperidin-1-yl) ethan-1-ol benzenesulfonate in crystalline form.SELECTED DRAWING: Figure 1

The invention provides a 2, 5-dimethylpyrazine production strain and a construction method and application thereof.According to the strain, key feedback inhibition is relieved through a perfect metabolic engineering strategy and strategies of knocking out a competitive pathway, introducing heterologous aminoacetone oxidase, deleting L-threonine efflux protein and the like, competitive enzyme conversion of aminoacetone is reduced through a system, and the 2, 5-dimethylpyrazine production strain is obtained. Spontaneous transformation of aminoacetone in Escherichia coli is enhanced, metabolism of L-threonine is expanded to synthesis of 2, 5-dimethylpyrazine, the yield of 2, 5-dimethylpyrazine is further increased, the constructed strain does not contain plasmids and has the advantages of clear genetic background, sustainable transformation and the like, and the 2, 5-dimethylpyrazine is produced through fermentation. The method is simple to operate, can be used for directly synthesizing 2, 5-dimethylpyrazine from the beginning by using a cheap carbon source, and has a very good application prospect.

The present invention provides a compound represented by the following Formula (I):wherein ring A is a C5-C7 non-aromatic carbocycle or a 5- to 7-membered non-aromatic heterocycle; ring B is a benzene ring or the like; Q is —NHC(O)— or a 5-membered aromatic heterocycle; R1 is each independently halogen or the like; R2a and R2b are each independently hydrogen, alkyl, or haloalkyl; R3 is alkyl or the like; R4 and R5 are each independently hydrogen or the like; R6 is each independently halogen, alkyl, haloalkyl, alkyloxy, haloalkyloxy, or alkyloxyalkyl; n is an integer of 1 to 3; and m is an integer of 0 to 3.

The invention provides new pyrazine derivatives of formula (I): (I) or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

The present application belongs to the technical field of electronic atomization, and particularly relates to a tobacco extract composition, a preparation method and application thereof. The tobacco extract composition comprises 2,6-dimethylpyrazine, 3-acetylpyridine, dihydroactinidiolide, cembranoid diol, maackiain, furfuryl alcohol and guaiacol. The mass ratio of (2,6-dimethylpyrazine+3-acetylpyridine) to dihydroactinidiolide is greater than 0.02; the dihydroactinidiolide content is greater than or equal to 0.02 mg / g in terms of dry matter mass; and the guaiacol content is 0.004-0.025 mg / g. The overall roasting characteristics are sufficient, and the smoke-like feeling is strong. The preparation method comprises the following steps: first extracting tobacco raw materials to obtain extract A, low-temperature secondary extraction of the extract A to obtain tobacco flavor, high-temperature secondary extraction of the extract A to obtain smoke flavor, and mixing the tobacco flavor and the smoke flavor in a certain proportion to obtain the tobacco extract composition.

The invention provides an application of CC-115 in preparation of an anti-new coronavirus drug. The chemical name of the CC-115 is 1-ethyl-7-[2-methyl-6-(1H-1, 2, 4-triazole-3-yl) pyridine-3-yl]-3, 5-dihydropyrazino [2, 3-b] pyrazine-2 (1H)-ketone, and the structural formula of the CC-115 is shown in the description. An in-vitro Vero cell infection model finds that the CC-115 can inhibit the replication of a new coronavirus (SARS-CoV-2) original strain and an Omicro variant (EG.5.1), and the IC50 (half maximal inhibitory concentration) of the CC-115 aiming at the SARS-CoV-2 original strain is 0.004 [mu] M and 0.005 [mu] M. The CC-115 has the advantages that the CC-115 can inhibit the replication of the SARS-CoV-2 original strain and the Omicro variant (EG.5.1); the CC-115 can be used for research and development of anti-new coronavirus infection drugs, and has a good development prospect.

Certain substituted pyrazine-2-carboxamides of formula (I), and pharma- ceutically acceptable salts thereof, are disclosed, along with compositions containing them, and their use in therapy. The compounds are inhibitors of hematopoietic progenitor kinase 1 (HPK1), and are therefore particularly useful in the treatment or prevention of cancer. [Case 1] TIFF2024527623000305.tif30161

The present invention relates to a pyrazine macrolide compound and the use thereof. Specifically disclosed is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits activity against bacteria, mycoplasmas, or chlamydias, and is useful for preventing and / or treating diseases caused by bacteria, mycoplasmas, or chlamydias. Further, the compound of the present application can achieve an antibacterial activity comparable to or better than that of azithromycin or solithromycin at a lower dosage. Furthermore, the compound of the present application achieves a superior antibacterial effect on Gram-positive bacteria. Still furthermore, the compound of the present application exhibits a better inhibitory activity against mycoplasmas and a lower hepatotoxicity.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.

The application discloses a modified 2,6-diamino-3,5-dinitropyrazine-1-oxide-based hybrid energetic material with a high decomposition rate, a preparation method and application, and relates to the technical field of composite materials. The method first obtains an energetic high-nitrogen two-dimensional material (TAGP) formed by cross-linking of triaminoguanidine nitrate (TAGN) and an aldehyde solvent, and then uses the TAGP as a template material to induce LLM-105 to crystallize, so as to obtain an LLM-105 / TAGP composite energetic material through separation, washing and drying. The LLM-105-based composite energetic material provided by the application has the characteristics of a greatly improved thermal decomposition rate, and the decomposition rate is improved by 50% compared with that of LLM-105 raw materials, and the composite energetic material has high safety of LLM-105. The preparation process is mild, safe, environmentally friendly and easy to scale up, and is expected to be applied to the field of high-energy and safe propellant charges.

The invention provides a polymorphic form of a compound (Z)-3-{3-[3, 5-bis (trifluoromethyl) phenyl]-1H-1, 2, 4-triazole-1-yl}-N '-(pyrazine-2-yl) acryloyl hydrazide shown as a formula (I), and the polymorphic form provided by the invention has better chemical stability, physical stability and lower hygroscopicity, is less influenced by heat, humidity and illumination, and is convenient to store and prepare. The invention further provides a preparation method of the polymorphic form of the compound (Z)-3-{3-[3, 5-bis (trifluoromethyl) phenyl]-1H-1, 2, 4-triazole-1-yl}-N'-(pyrazine-2-yl) acryloyl hydrazide.

The invention provides a crystal form VI of an acrylamide compound, and the acrylamide compound is (S)-N-(5-((6-(2-(7, 7-dimethyl-1-oxo-1, 3, 4, 6, 7, 8-hexahydro-2H-cyclopentane [4, 5] pyrrolo [1, 2-a] pyrazine-2-yl)-3-(hydroxymethyl) pyridine-4-yl)-4-methyl-3-oxo-3, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-3-(hydroxymethyl) pyridine-4-yl)-4-methyl-3-oxo-3, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-3-(2, 3, 4-triazolo [1, 2-a] pyrazine-2-yl)-4- The crystal form VI is a 2-(2, 4-dihydropyrazine-2-yl) amino)-2-(2-methyl-4-(tetrahydro-2H-pyran-4-yl) piperazine-1-yl) 5phenyl) acrylamide compound, and an X-ray powder diffraction pattern of the crystal form VI comprises diffraction peaks with the following 2 theta angle values: 8-3 + / -0.2 degrees, 13.2 + / -0.2 degrees and 18.9 + / -0.2 degrees. The crystal form VI has the advantages of good stability and low hygroscopicity, and is suitable for industrial production of bulk drugs and development of preparation prescriptions.

The present disclosure provides a solid form of 5-fluoro-1-(((5S, 7S, 8R)-8-fluoro-3-(5-(2-hydroxypropyl-2-yl) pyrazin-2-yl)-7-methyl-2-oxo-1-oxa-3-azaspiro [4.5] decane-7-yl) methyl)-1H-benzo [d] imidazole-6-formonitrile: which is useful as a TRPV4 antagonist.

One aspect of the present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is a phenyl group or a 5- or 6-membered heteroaryl group; Ring B is absent or is phenyl, pyridinyl, pyrazidinyl, pyrazinyl, pyrimidinyl, oxazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, isothiazolyl or thiazolyl; Ring C is a fused bicyclic group of formula: (AA), wherein X1 to X9 form a substituted heteroaryl group containing at least one N and at least one NH; X-Y is -(CH2) m NR 21 CO; L is a direct bond or a linker group; Z is selected from alkyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl, each of which may be substituted; each R a and each R b is independently selected from alkyl, halo, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, cyano, NR 23 COR 25 、NR 24 -SO2R 26 、(CH2) q SR 27 、(CH2) q SOR 28 、(CH2) q SO2R 29 、SO2NR 30 R 31 、(CH2) q OH、(CH2) q OR 32 、NR 33 R 34 、CONR 35 R 36 、cycloalkyl and (CH q 2)-heterocycloalkyl; R 10 、R 11 、R 21 、R 22 、R 23 and R 24 are each independently selected from H and alkyl; R 12 ~R 20 、and R 25 ~R36 Each of the following is independently selected from H, alkyl, aralkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, and cycloalkyl; each of m, n, and p is independently an integer from 0 to 4; and each of q is independently an integer from 0 to 4. Further aspects of the present invention relate to pharmaceutical compositions comprising the compounds according to the present invention and the use of the compounds in the treatment of various GPR35-related disorders. [Formula 1] TIFF2026510355000540.tif56170

The application belongs to the technical field of photovoltaic devices, and relates to preparation and application of a multifunctional organic additive doped CsSnI3 perovskite film; during preparation, a perovskite spin coating liquid is spin coated on an ITO glass substrate to form a precursor film, and the precursor film is subjected to annealing treatment to obtain a CsSnI3 perovskite film; the perovskite spin coating liquid is formed by adding stannous fluoride and 3-amino-pyrazine-2-carboxamide (3-APCA) to a perovskite precursor solution and stirring; the perovskite precursor solution is formed by dissolving cesium iodide and stannous iodide in an organic solvent; and the application is applied to solar cells, light-emitting diodes, photoelectric detectors, photoelectric catalysis and energy storage. The method introduces the multifunctional organic additive 3-APCA, realizes Sn 2+ oxidation inhibition, optimizes film crystallinity and passivates defects, and significantly improves the quality of the CsSnI3 perovskite film; and the application range is wide.

The application provides a method for promoting the absorption of calcium elements by pineapple fruits, which comprises the following steps: three months after the pineapple plant is induced to bloom and four months after the pineapple plant is induced to bloom, gauze is soaked in an amino oxyacetic acid aqueous solution or a pyrazine amide aqueous solution, the soaked gauze is applied to the connection between the pineapple fruit and the fruit stem for 2-5 hours; the gauze is secondly soaked in an indole-3-acetic acid aqueous solution, an indole-3-butyric acid aqueous solution, a phenylacetic acid aqueous solution or an alpha-naphthylacetic acid aqueous solution, and the soaked gauze is again applied to the connection between the pineapple fruit and the fruit stem for 2-5 hours; the gauze is thirdly soaked in a 6-benzylaminopurine aqueous solution, a kinetin aqueous solution, a thidiazuron aqueous solution or a forchlorfenuron aqueous solution, and the soaked gauze is again applied to the connection between the pineapple fruit and the fruit stem for 2-5 hours. The application can inhibit the formation of the pineapple fruit stem delimitation, promote the absorption of calcium by the fruits, reduce the incidence of pineapple water core disease from about 18% to about 0.6%, and significantly improve the income of fruit farmers.

This invention belongs to the field of flavor enhancement technology and provides a method for enhancing the binding of pea protein isolate to 2,5-dimethylpyrazine using nanocellulose. The method involves mixing pea protein isolate, nanocellulose, and water; the resulting first mixture is then hydrated and gelled sequentially to obtain a gel system; this gel system is then mixed with 2,5-dimethylpyrazine to obtain a second mixture, which is then combined to enhance the aroma of 2,5-dimethylpyrazine. This invention introduces nanocellulose, achieving efficient adsorption and stable retention of the flavor compound 2,5-dimethylpyrazine in the pea protein isolate system.

The invention belongs to the technical field of microbial fermentation, and particularly relates to rhodotorula mucilaginosa JQRM001 and application thereof. The invention provides a rhodotorula mucilaginosa JQRM001, the Latin name of the rhodotorula mucilaginosa JQRM001 is Rhodotorula mucilaginosa, the rhodotorula mucilaginosa JQRM001 is preserved in China General Microbiological Culture Collection Center, the address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation date is July 15, 2025, and the preservation number is CGMCC No.35240. The invention further provides a preparation method of the rhodotorula mucilaginosa. The rhodotorula mucilaginosa JQRM001 not only has excellent performance of high temperature resistance and acid resistance, but also can be used for specifically synthesizing alkylpyrazine flavor substances and remarkably improving the antioxidant activity of plant polysaccharides.

This invention relates to the field of oilfield chemical additives technology, and discloses a method for preparing a 1-benzyl-10-phenylpyrrolo[1,2-a:3,4-b']dipyrazine-1-onium type quaternary ammonium salt high-temperature acidizing corrosion inhibitor. The method uses 2,2'-piperazine as the starting material, which undergoes a quaternization reaction with benzyl bromide to obtain a quaternary ammonium salt intermediate. The obtained intermediate undergoes an oxidative cyclization reaction with benzaldehyde and manganese dioxide in a dichloromethane system. After separation, drying, and purification, the target product is obtained. The preparation process of this invention is simple and easy to control, the product is easy to purify, and it is suitable for industrial production. It exhibits good synergistic effects with additives, excellent water solubility and compatibility, can stabilize and protect steel, reduce construction risks, and is suitable for various high-temperature acidizing operations.

Disclosed herein are 3-[(1H-pyrazol-4-yl)oxy]pyrazin-2-amine compounds of Formula (I), or stereoisomers thereof, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. Also disclosed are methods for modulating, e.g., inhibiting or treating, HPK1-related disorders or diseases, including cancer, by using the compounds disclosed herein. [Formula 1] JPEG2023543212000422.jpg63165

Provided is a composition capable of suppressing generation of a trimer even when an aliphatic aldehyde at a high concentration of 90 mass% or more is stored at a low temperature. The composition contains 90 mass% or more of an aliphatic aldehyde having 8-16 carbon atoms and 100 ppm or more and 1 mass% or less of an additive with respect to the mass of the aliphatic aldehyde, wherein the additive is one or more selected from the group consisting of polyalkylene glycol derivatives represented by formula (I), sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol fatty acid esters, amino acids represented by formula (II), anthranilic acid esters represented by formula (III), and pyrazine derivatives represented by formula (IV).

The application belongs to the technical field of detection and analysis, and discloses a normal phase detection method for imine reaction control. The method is detected by normal phase liquid chromatography, and the detection conditions include: a polysaccharide derivative normal phase coated type chiral chromatographic column is used, and a mixed solution of n-hexane, ethanol, ethylenediamine and trifluoroacetic acid is used as the mobile phase, wherein the volume ratio of n-hexane, ethanol, ethylenediamine and trifluoroacetic acid is (75-85):(15-25):(0.05-0.15):(0.05-0.15). The method can realize effective separation, detect the content of 1,2,3,4,10,14B-hexahydrodibenzo[C,F]pyrazino[1,2-A]azepine in the reaction solution, and has the advantages of simplicity, accuracy, rapidness and reliability.

The invention belongs to the technical field of medicines, and particularly relates to a 4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrazine derivative and application thereof. The derivative disclosed by the invention is a compound shown in a general formula (I) and pharmaceutically acceptable salts thereof, and A, L and Q are described in the specification. The compound disclosed by the invention has relatively strong ROCK2 inhibitory activity in vitro, and can be used for treating ROCK2 related diseases, such as chronic graft versus host disease, tumor or fibrosis and the like.

The present application relates to a kind of iron ion detection fluorescent probe, application and fluorescence detection method, belong to iron content detection technical field, solve the technical problems such as the operation of the iron content detection in magnesium oxide is complicated, time-consuming etc..The preparation steps of fluorescent probe are as follows: step one, pyrazine-2,3,5,6-tetramethylic acid and Zn(NO) 3 are weighed and dissolved in the mixed solvent of N,N-dimethylformamide and dimethyl sulfoxide, after stirring, mixed solution is obtained;Step two, the mixed solution obtained in step one is placed in oven and continuously heated, white transparent block crystal is obtained, after washing, filtering, drying and grinding, the fluorescent probe is obtained.The present application synthesizes a new type of zinc-based compound by solvothermal method, as fluorescent probe is used for the fluorescence detection of iron ion in magnesium oxide, can realize the trace detection of iron ion to screen out low magnetic magnesium oxide with iron content meeting industry standard requirements.